PTC THERAPEUTICS, INC. Operating Income Loss

• PTC THERAPEUTICS, INC. showed an increase of +386.5% in Operating Income Loss from 2024 to 2025.
• This data is from PTC THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), PTC THERAPEUTICS, INC.'s Operating Income Loss has grown by 2,734.8%.
• Historical annual values: Fiscal year 2025: $866.94 million | Fiscal year 2024: -$302.57 million | Fiscal year 2023: -$439.50 million | Fiscal year 2022: -$447.41 million | Fiscal year 2021: -$374.44 million | Fiscal year 2020: -$431.77 million | Fiscal year 2019: -$241.16 million | Fiscal year 2018: -$115.69 million | Fiscal year 2017: -$64.29 million | Fiscal year 2016: -$132.06 million | Fiscal year 2015: -$167.13 million | Fiscal year 2014: -$99.41 million | Fiscal year 2013: -$45.40 million | Fiscal year 2012: -$26.81 million | Fiscal year 2011: $30.58 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026